Background Repurposing medications that have demonstrated efficacy experimentally for drug-resistant tuberculosis (TB), such as statins, provides an opportunity to sidestep the time span and financial resources required to produce new antimicrobials to surmount resistance. However, this has not been extensively explored particularly in sub-Saharan Africa. This study investigated the benefits of statins as adjunct therapy in patients with TB, including those that are drug-resistant. Methods This was a case control study, involving the review of 3-year medical record of patients with tuberculosis on TB therapy with statins as adjunct (the cases), and those on TB therapy but not on statins at the Agogo Presbyterian Hospital in Ghana. The data obtained was analyzed using STATA version 17. Chi square test was used to determine the association between statin use as adjunct for TB therapy and improved outcomes (cure rate). Results Statin use in TB therapy as adjunct was associated with an increased incidence of TB cure (p<0.001). The relationship between statin and TB cure was still statistically significant, when age was adjusted for as a confounder in statin exposed individuals, (RR=4.9, p<0.05). Additionally, statins increased the cure rate of TB in the population studied, 6.61 per 100 population, 95% CI, (4.05-10.79) compared to 1.30 per 100 population 95% CI, (0.65-2.59) in the absence of statins. Conclusion Statin use in patients on TB therapy was associated with increased cure. This study has affirmed that statins have potential benefits as an adjunct therapy in TB management.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Kwame Nkrumah University of Science and Technology Committee on Human Research, Publications, and Ethics (CHRPE/AP/528/22).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its supporting information files.